Jul 29, 2024 Press Releases
PDF Version AT-02 has been granted COMP positive opinions for orphan medicinal product designations in the EU for both ATTR and AL amyloidosis. AT-02 is the Company’s lead pan-amyloid removal therapeutic candidate in development. AT-02 is currently being evaluated in...
Dec 19, 2022 Press Releases
PDF Version SAN FRANCISCO – December 19, 2022 – Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced today that the European Commission (EC) and European...